United States - English - NLM (National Library of Medicine)

medunik usa - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - pheburane is indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (ucds), involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc) or argininosuccinic acid synthetase (as). limitations of use episodes of acute hyperammonemia may occur in patients while on pheburane. pheburane is not indicated for the treatment of acute hyperammonemia, which can be a life-threatening medical emergency that requires rapid acting interventions to reduce plasma ammonia levels. none risk summary available data with sodium phenylbutyrate use in pregnant women are insufficient to identify a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with sodium phenylbutyrate. based on published animal data, phenylacetate may be neurotoxic to the developing brain (see data) . there are serio

Australia - English - Department of Health (Therapeutic Goods Administration)

orpharma pty ltd - sodium phenylbutyrate, quantity: 483 mg/g - granules - excipient ingredients: povidone; ethylcellulose; hypromellose; macrogol 1500; sucrose; hydrolysed maize starch - pheburane (sodium phenylbutyrate) is indicated for the management of hyperammonaemia associated with urea cycle disorders. pheburane? should be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, and protein-free calorie supplements)

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - potassium chloride, quantity: 223 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 01 jan 1991 : the treatment of potassium depletion in patients with hypokalaemia; treatment of digitalis intoxication. iv administration is indicated when the patient is unable to take potassium orally or if hypokalaemia is severe.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - monobasic sodium phosphate, quantity: 1.936 g - tablet, effervescent - excipient ingredients: potassium bicarbonate; citric acid; sucrose; macrogol 4000; saccharin sodium; sodium bicarbonate; flavour - 1) hypercalcaemia associated with such conditions as hyperparathyroidism, multiple myelomatosis, and metastatic bone disease.,2) hypophosphataemia associated with vitamin d resistant rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - metaraminol tartrate, quantity: 5.7 mg - injection - excipient ingredients: sodium chloride; sodium metabisulfite; water for injections; sodium hydroxide; tartaric acid - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma.,it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - metaraminol tartrate, quantity: 9.5 mg - injection - excipient ingredients: sodium chloride; water for injections; sodium metabisulfite; sodium hydroxide; tartaric acid - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma.,it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - methylene blue, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - methylene blue injection usp is indicated: for the treatment of drug-induced methaemoglobinaemia; for the treatment of idiopathic methaemoglobinaemia (in which structural abnormality of haemoglobin is not present); as a bacteriological strain as a dye in diagnostic procedures such as fistula detection; for the delineation of certain body tissues during surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - magnesium sulfate heptahydrate, quantity: 500 mg/ml - injection, concentrated - excipient ingredients: water for injections - parenteral administration of magnesium is indicated in the treatment of acute hypomagnesaemia. magnesium salts are also indicated to prevent hypomagnesaemia in patients receiving total parenteral nutrition. magnesium sulphate is also indicated in the prevention and treatment of life-threatening seizures in the treatment of toxemias of pregnancy (pre-eclampsia and eclampsia). for emegency treatment of some arrhythmias such as torsade de pointes and those associated with hypokalemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - paraldehyde, quantity: 5 ml - injection, solution - excipient ingredients: hydroquinone - paraldehyde has been used as a sedative and hypnotic in a variety of clinical situations, although it has been largely replaced by safer and/or more effective agents. it may also be used in the treatment of convulsive episodes arising from tetanus, status epilepticus and poisoning by convulsive drugs, when other agents are inappropriate or ineffective. paraldehyde may be effective in reducing the anxiety associated with withdrawal from drugs such as narcotics or barbiturates, as well as in the management of acute agitation or delirium tremens due to alcohol withdrawal. paraldehyde is only recommended for use in these conditions when other treatments are ineffective or deemed inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - calcium chloride dihydrate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - parental administration of calcium is indicated in the treatment of hypocalcaemia where rapid increase in plasma calcium is required, such as in hypocalcaemic tetany and tetany due to parathyroid deficiency. intravenous calcium is also indicated to antagonise the cardiotoxicity of hyperkalaemia.